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Background: Current development efforts of subunit vaccines against Toxoplasma gondii, the etiological agent of
toxoplasmosis, have been focused mainly on tachyzoite surface antigen 1 (SAG1). Since microparticles made from
poly (lactide-co-glycolide) (PLG) polymers have been developed as safe, potent adjuvants or delivery systems, we
aimed to encapsulate recombinant SAG1 (rSAG1) with the PLG polymers to prepare PLG-encapsulated rSAG1
(PLG-rSAG1) microparticles that would sustain rSAG1 release and generate long-lasting protective immunity
against T. gondii in BALB/c mice.
Methods: In the present study, rSAG1 was encapsulated into PLG microparticles by the double emulsion method.
PLG-rSAG1 microparticles were then intraperitoneally injected twice at a 14-day interval into BALB/c mice. We
examined the ability of PLG-rSAG1 microparticles to induce and prolong effective anti-Toxoplasma immune
responses, in comparison with rSAG1 formulated with a Vet L-10 adjuvant (rSAG1 (Vet L-10)). Eight weeks after the
last immunization, protective activities were also evaluated after a lethal subcutaneous challenge of 1x104 live
T. gondii tachyzoites.
Results: PLG-rSAG1 microparticles, 4.25~6.58 micrometers in diameter, showed 69%~81% entrapment efficiency.
The amount of released rSAG1 protein from microparticles increased gradually over a 35-day period and the
protein still retained native SAG1 antigenicity. Intraperitoneal vaccination of mice with the microparticles resulted in
enhanced SAG1-specific IgG titers as well as lymphocyte proliferation and, more importantly, these enhanced
activities were maintained for 10 weeks. In addition, eight weeks after the last immunization, maximum production
of gamma interferon was detected in mice immunized with PLG-rSAG1 microparticles. Furthermore, 80% (8/10)
of mice immunized with PLG-rSAG1 microparticles survived at least 28 days after a lethal subcutaneous tachyzoite
challenge.
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Conclusions: Encapsulation of rSAG1 into PLG microparticles preserves the native SAG1 antigenicity and sustains
the release of rSAG1 from microparticles. PLG-rSAG1 microparticles can effectively induce not only significant
long-lasting SAG1-specific humoral and cell-mediated immune responses but also high protection against T. gondii
tachyzoite infection. Our study provides a valuable basis for developing long-lasting vaccines against T. gondii for
future use in humans and animals.
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microparticlesBackground
Toxoplasma gondii, the etiological agent of toxoplasmosis,
is an intracellular protozoan parasite. T. gondii is wide-
spread throughout the world and uses felines as final hosts
and various endothermic animals, including humans, as
intermediate hosts [1]. Toxoplasmosis imposes adverse eco-
nomic impact due to the induction of severe abortion and
neonatal loss of domestic animals [2]. In pregnant women,
infection may give rise to serious fetal congenital mental
retardation, blindness and hydrocephaly [3]. Toxoplasmosis
is also a major opportunistic infection in immunocom-
promised individuals, often resulting in lethal toxoplasmic
encephalitis [4].
Vaccines against T. gondii have been investigated for a
long time. Although one attenuated vaccine has been suc-
cessfully used to reduce abortions in sheep [5], it has a
very short shelf-life and is unlikely to be used in humans
[6]. In addition, many inactivated vaccines developed in
the past have produced only little to moderate protective
efficacy against infections with a lethal challenge dose of
the virulent strain of T. gondii [7,8]. Current development
efforts of subunit vaccines against the parasite have been
focused mainly on the major immunodominant surface
antigens of T. gondii tachyzoites [7], the rapidly multi-
plying stage during the acute phase infection. Among
them, the surface antigen 1 (SAG1) has been identified to
be involved in the process of host-cell invasion [9]. In
addition, numerous studies have shown that vaccination
with SAG1 in mice elicits a specific immune response and
protection against T. gondii infection [6,7]. Therefore, the
tachyzoite SAG1 can be considered as a possible candidate
antigen for Toxoplasma vaccine development.
In our previous work, we cloned the SAG1 sequence
to produce a recombinant SAG1 (rSAG1) protein with a
molecular weight of 30 kDa [10]. However, further
protection analysis in mice demonstrated that rSAG1
emulsified with an oil adjuvant, Vet L-10, did not
fully protect animals (60%) against a lethal subcuta-
neous challenge of T. gondii tachyzoites [10]. Thus,
alternative potent adjuvants that can enhance the
rSAG1 immunogenicity are needed to improve such
moderate anti-Toxoplasma protection induced by the
oil-formulated vaccine.On the other hand, cell-mediated immunity is considered
as the major mechanism in the prevention of T. gondii infec-
tion [7,11]. Th1-type cytokines, gamma interferon (IFN-γ)
especially [12], secreted from CD4+ Th1 cells can subse-
quently activate CD8+ Tc cells to turn into major cytotoxic
effector cells for lysing tachyzoite-infected cells, limiting
parasite dissemination during the phase of acute infection
[11] as well as inhibiting cyst formation during chronic in-
fection [7]. These facts indicate that effective protection
against T. gondii infection is critically dependent on the
IFN-γ-associated Th1 cell-mediated immunity. Therefore,
effective and trustworthy vaccines comprising subunit or re-
combinant antigens, such as rSAG1, formulated with potent
adjuvants that are promised to induce an IFN-γ-associated
Th1 cell-mediated immune response seem more likely to be
approved for use.
In recent years, microparticles made from biodegrad-
able and biocompatible polymers, such as poly (lactide-
co-glycolide) (PLG), have been used as safe, potent
adjuvants or delivery systems to encapsulate antigens
for preparing controlled-release microparticle vaccines
[13-15]. Adjuvant effects of PLG microencapsulation can
protect antigens from unfavorable proteolytic degradation
[15], allow the sustained and extended release of antigens
over a long period [16], and facilitate antigen uptake via
antigen-presenting cells (APCs) [15-18]. These effects in
turn reinforce the antigen immunogenicity to favorably
generate a strong immune response, especially Th1 cell-
mediated immunity [13-15]. In other words, microparticle
vaccines made from PLG polymers may fulfill the need for
induction of a functional cell-mediated immune response
against T. gondii. Although intranasal vaccination with one
PLG microparticle vaccine containing a tachyzoite extract
plus a mucosal adjuvant, cholera toxin, was described in
sheep, the immune response produced was not sufficient to
protect sheep against sporulated oocysts [19], indicating
that other yet undefined factors are required.
In the present study, in order to enhance the rSAG1
immunogenicity, the PLG polymers were used as a
potent adjuvant to encapsulate rSAG1 for preparing a
controlled-release microparticle vaccine. The resulting
PLG-encapsulated rSAG1 (PLG-rSAG1) microparticles
were then injected intraperitoneally into BALB/c mice.
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induce and prolong effective anti-Toxoplasma immunity,
in comparison with rSAG1 formulated with a Vet L-10
adjuvant (rSAG1 (Vet L-10)). Protective activities were
also evaluated after a lethal subcutaneous challenge of T.
gondii tachyzoites. We found that PLG encapsulation
preserved the native SAG1 antigenicity, resulted in
sustained release of rSAG1 for an extended period and,
finally, allowed PLG-rSAG1 microparticles to induce and
maintain humoral and cell-mediated immune responses
against T. gondii in mice.
Methods
Mice and parasite antigens
Female ICR and BALB/c mice (6~8 weeks of age) were
purchased from the National Laboratory Animal Center,
National Science Council, Taiwan. In this study, ICR mice
were used to maintain and passage T. gondii tachyzoites,
while BALB/c mice were used in the immunization experi-
ments. Mice were housed in high containment facilities
and managed in compliance with the Animal Welfare Act.
All administrations were reviewed and approved by The
Institutional Animal Care and Use Committee, National
Pingtung University of Science and Technology.
The tachyzoites of T. gondii (RH strain) used in this study
were kindly provided by Dr. David Chao (Department of
Biological Science, National Sun Yat-sen University,
Kaohsiung, Taiwan) and maintained in ICR mice. The
tachyzoites harvested from the peritoneal fluid of ICR mice
infected intraperitoneally 2 days earlier with tachyzoites
were washed three times with saline (150 mM NaCl),
filtered through a 5-μm membrane (Millipore), and
then concentrated by centrifugation at 2,000 × g for
10 min. Purified tachyzoites were then resuspended in
a 10-fold volume of PBS (140 mM NaCl, 8.2 mM
Na2HPO4, 1.5 mM KH2PO4, 2.7 mM KCl, pH 7.3),
left at 4°C for 30 min, sonicated by using a VCX 130
ultrasonic processor (Sonics) equipped with a 3-mm
diameter CV18 probe (30% of maximum power for
four 10-sec pulses with 20-sec cooling between
pulses), and then centrifuged at 12,000 × g for 30 min
at 4°C. The resulting soluble supernatant was used as
the tachyzoite sonicated antigen (TsoAg).
The rSAG1 protein used in the present study was pro-
duced according to the previous study [10]. The SAG1
gene was re-cloned into the plasmid pGEX-6P-1 (GE
Healthcare) and expressed as a glutathione-S-transferase
(GST) fusion protein in BL21 (DE3) Escherichia coli
(Yeastern Biotech). Briefly, SAG1 specific primers were
designed (the forward primer: 5’-CCGGAATTCATG
TCGGTTTCGCTGCACCACTTCAT-3’ and the reverse
primer: 5’-CGCCCCGGGCGCGACACAAGCTGCGAT
AGAGCC-3’ respectively contained the underlined EcoRI
sequence as well as the underlined SmaI sequence) tocarry out the SAG1 PCR amplification as before [10]. The
amplified SAG1 fragment was digested with restriction
enzymes EcoRI and SmaI (TOYOBO) and inserted into
the EcoRI/SmaI sites of pGEX-6P-1, termed pGEX-SAG1.
The recombinant plasmid was then transformed into
BL21 (DE3) E. coli. After cloning, the induced fusion
protein, GST-SAG1, was purified and its tag GST
protein was removed as described previously [10].
The resulting recombinant protein, rSAG1 (30 kDa),
was successfully prepared and its antigenicity was
analyzed by Western blotting.
The protein concentrations of TsoAg and rSAG1
were determined by using the dye-binding DC protein
assay (Bio-Rad) with bovine serum albumin (BSA) as a
standard. Aliquots of these proteins were stored at −20°C
until use.
Monoclonal antibody (mAb)
The anti-SAG1 mouse mAb TG-1 (isotype G, subclass 1, κ
light chain) used as a marker for SAG1 (30 kDa) in the
present study was prepared as before [20], with minor
modifications. BALB/c mice were subcutaneously injected
twice at a two-week interval with TsoAg (50 μg) emulsified
with Freund’s adjuvant (Sigma). Two weeks after the sec-
ond immunization, each mouse was injected intravenously
with 10 μg of TsoAg. One week later, spleen cells isolated
from the immunized mice were fused with NS-1 myeloma
cells (BCRC66036), which are sensitive to HAT (hypoxan-
thine-aminopterin-thymidine) (Sigma), in the presence of
50% polyethylene glycol (Sigma) for 1 min at 37°C and
then cultured in 96-well culture plates with the HAT selec-
tion medium for one week. Wells with clones were
screened for antibody production by enzyme-linked
immunosorbent assay (ELISA). The hybridoma cells
producing high anti-TsoAg titers were cloned by limiting
dilution and then cultured for collecting mAb-containing
supernatant media. The IgG fraction in the media was
purified by the protein A agarose affinity column (Bio-Rad)
and its specificity to SAG1 was determined by Western
blotting. In addition, the mAb isotype was further
determined by the IsoQuick™ isotyping kit (Sigma).
Microparticle preparation
The rSAG1 protein was encapsulated in 50:50 poly
(lactide-co-glycolide) (Sigma) using the water/oil/water
double emulsion solvent evaporation technique as
described previously [21,22], with minor modifica-
tions. Briefly, 10 ml of a 6% solution of PLG polymer
in dichloromethane (Sigma) was mixed with 2 ml of a
rSAG1 solution (5 mg/ml) using a PRO200 homogenizer
(PRO Scientific) equipped with 10 mm × 150 mm
generator at 12,000 rpm for 3 min to produce a water/
oil emulsion. The resulting emulsion was further homo-
genized with 20 ml of a 2.5% polyvinyl alcohol (Sigma)
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water/oil/water emulsion. The water/oil/water emulsion
was then stirred for 18 h at room temperature (RT)
and pressurized to promote solvent evaporation and
PLG-rSAG1 microparticle formation in a laboratory
fume hood. The microparticles were collected by
centrifugation at 4,000 × g for 30 min, washed three
times with distilled water to remove non-entrapped
rSAG1 and then lyophilized by a FD-5030 freeze
dryer (Panchum) for storage at −20°C.
Microparticle size and morphology
A total of 5 mg of freeze-dried PLG-rSAG1 microparticles
was resuspended in 1 ml of deionized water in a 1.5 ml
microfuge tube by vortexing. The particle size (diameter)
was determined by N5 submicron particle size analyzer
(Beckman Coulter). All measurements were performed in
triplicate on samples from different batches. In addition,
the particle morphology was inspected using scanning
electron microscopy. The particle suspension was dropped
onto stubs and allowed to air dry. After drying, the speci-
mens were sputter-coated with gold and imaged with a
S3000N scanning electron microscope (Hitachi).
Protein entrapment in microparticles
A total of 5 mg of PLG-rSAG1 microparticles was first dis-
solved in 500 μl of 0.1 M NaOH with 2.5% SDS to extract
the encapsulated rSAG1 as described previously [22]. After
4 h at 37°C, the extraction was terminated by adding 500 μl
of 0.1 M HCl. After centrifugation at 12,000 × g for 10 min,
the content of rSAG1 in the supernatant was assessed
with the BCA protein assay (Pierce) and compared to
BSA standards and adjusted against empty PLG
microparticles. Based on this result, the ratio (w/w) of
rSAG1 entrapped per dry weight of microparticles was
determined and the entrapment efficiency (%) was
expressed as a ratio of the actual rSAG1 entrapment to the
theoretical rSAG1 entrapment by using the formula [22]:
Actual rSAG1 entrapment w=wð Þ
Theoretical rSAG1 entrapment w=wð Þ  100. All measurements were
performed in triplicate on samples from different batches.
In vitro release study
A total of 5 mg of PLG-rSAG1 microparticles was sus-
pended in 1 ml of PBS with 0.02% sodium azide and
shaken at 37°C in 1.5 ml microfuge tubes. One milliliter
of supernatant was sampled daily by centrifugation at
4,000 × g for 30 min and an additional 1 ml of fresh PBS
was immediately added to the microfuge tubes in order
to incubate as before [23]. The collected samples were
neutralized and the amount of rSAG1 in the supernatant
was measured using the BCA protein assay (Pierce),
compared with BSA standards and adjusted against
empty PLG microparticles. In addition, Western blotanalysis using the mouse mAb TG-1, which is specific to
SAG1 (30 kDa) of T. gondii tachyzoites, was performed
to determine if released rSAG1 samples on days 1, 7, 14,
21, 28 and 35 exhibited the native SAG1 antigenicity.
The released rSAG1 samples (500 μl) on days 1, 7, 14,
21, 28 and 35 were first concentrated 10-fold using the
Amicon Ultra-0.5 Centrifugal Filter Device (10 kDa
limit) (Millipore). The same volume (10 μl) of each
concentrated rSAG1 sample was then separated by 12%
SDS-PAGE and analyzed with mouse mAb TG-1 as
described previously [10].
Intraperitoneal immunization of mice
Five groups of 30 BALB/c mice each were intraperitoneally
injected twice at a 14-day interval with PBS, blank PLG, 10
μg of soluble rSAG1 alone, 10 μg of rSAG1 emulsified with
Vet L-10 (Invitrogen) oil adjuvant (rSAG1 (Vet L-10)) as
described previously [10] or PLG-rSAG1 microparticles
containing 10 μg of rSAG1. Specific anti-Toxoplasma
immune responses were analyzed by the following
immunoassays.
Antigenic specificity of immunized sera
Two weeks after boosting, Western blot analysis was
performed to further study the antigenic specificity of
the immunized mouse sera. Briefly, aliquots of TsoAg
(20 μg/well) were separated by 12% homologous
SDS-PAGE and electrophoretically transferred to a
polyvinylidene difluoride membrane (Millipore). After
blocking, strips of the membrane were cut and probed
with sera from mice immunized with PLG-rSAG1 micro-
particles, rSAG1 (Vet L-10), soluble rSAG1 alone, PLG or
PBS for 1 h at 37°C. Incubation with mAb TG-1 was also
conducted. IgG-bound antibodies on strips were detected
with alkaline phosphatase-conjugated, 1:1,000-diluted goat
anti-mouse IgG (Zymed) and the color development was
then processed as described previously [10].
Serum IgG titer assay
Following immunization, mouse sera were collected
every two weeks and their IgG titers were measured
by using ELISA as described previously [24], with
minor modifications. Flat-bottomed 96-well polystyrene
microplates (Nunc) were coated with 100 μl/well of TsoAg
(10 μg/ml) in 0.1 M carbonate/bicarbonate buffer (pH 9.4)
and incubated overnight at 4°C. Each well was then
washed with PBS and blocked with the blocking buffer
(PBS containing 5% BSA). Samples of 1:50 diluted serum
in serial dilution were added to wells (50 μl/well)
and incubated for 1.5 h at 37°C. After three washes
with PBS-T (PBS with 0.05% Tween 20), wells were
incubated with biotinylated goat anti-mouse IgG anti-
body (Zymed) diluted in the blocking buffer (1:3,000)
for 1 h at 37°C. The plates were subsequently washed
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was added. After incubation for 1 h at RT, plates were
washed again with PBS-T and then incubated with 100 μl/
well of tetramethylbenzidine substrate solution (Sigma) for
20 min in the dark. The enzymatic reaction was stopped
with 100 μl/well of 1 M H2SO4 and the absorbance at 450
nm was read by an ELISA reader. The titer was defined as
the reciprocal of the dilution that resulted in an absorbance
value that is 50% of the total value, obtained by subtracting
the background absorbance from maximum absorbance.
The maximum absorbance is the absorbance at the plateau
(around OD = 3.2~3.5) of the curve obtained by plotting
the OD versus serial dilution of sera of immunized mice in
a semi-logarithmical manner [24].
Lymphocyte proliferation assay
Following immunization, three mice per group were sacri-
ficed every two weeks to obtain spleen lymphocytes via
gradient isolation by Ficoll-Paque™ Plus (GE Healthcare)
under sterile conditions. The lymphocytes were then
cultured in triplicate in 96-well culture plates at a concen-
tration of 1 × 105 cells per well in 200 μl of RPMI-1640
culture medium (CM). The cells in each well were
stimulated with 10 μg/ml of TsoAg and incubated for
72 h at 37°C in 5% CO2. CM-treated cultures were
also conducted to use as controls. The lymphocyte
proliferation induced by TsoAg was monitored by
using the BrdU (5-bromo-2’-deoxyuridine) Colorimetric
Cell Proliferation ELISA (Roche) as described previously
[10,20]. BrdU labeling solution (20 μl/well) was added into
each well and incubated for an additional 12 h. Cells were
then centrifuged at 2,000×g for 20 min and dried for 1 h
at 60°C. Each well was fixed with 200 μl of the fixative
solution for 30 min at RT. After washing, wells were incu-
bated with the blocking reagent (200 μl/well) for 30 min
at RT. After another wash, 100 μl of mouse anti-BrdU
mAb conjugated peroxidase (1:100) was added to each
well. After incubation for 1 h at 37°C, wells were washed
and the substrate solution (100 μl/well) was added. The
reaction was stopped 30 min later with 50 μl/well of 1 M
H2SO4. The absorbance at 450 nm was measured. The
stimulation index (SI = OD450 values from TsoAg-treated
cultures/OD450 values from CM-treated control cultures)
of each group was calculated as described previously
[10,20] and expressed as the mean ± SD.
IFN-γ assay
Eight weeks after boosting (before challenge), parallel trip-
licate lymphocyte cultures derived from three mice of
each group were set up as per the procedure for prolifera-
tion assay. Cell cultures were stimulated with 10 μg/ml of
TsoAg or 0.5 μg/ml of Con A (Sigma), a T cell mitogen,
for 96 h at 37°C in 5% CO2. Cells stimulated with Con A
were used as controls. Cell-free supernatants wereharvested and their IFN-γ concentrations were analyzed
by the sandwich ELISA using the OptEIA Mouse IFN-γ
Set (BD Biosciences) according to the manufacturer’s
instructions [10,20]. The concentrations of IFN-γ were
determined by comparison to a standard curve created
with known amounts of standard recombinant mouse
IFN-γ and the sensitivity limit was 20 pg/ml.
Tachyzoite challenge
Eight weeks after boosting, five groups of 10 mice each
were challenged with a subcutaneous injection of 1 × 104
live tachyzoites of T. gondii (RH strain) in order to verify
whether the induced immune responses could protect
mice from tachyzoite infection. Mice were observed
daily for an additional 28 days and deaths were recorded
as they occurred. The survival rate (number of surviving
mice after challenge/number of tested mice in each
group) in each group was calculated as described
previously [10,20].
Statistical analysis
Particle size and entrapment efficiency of microparticles
from different batches, along with IFN-γ production
from different immunization groups, were statistically
compared using one-way ANOVA. Antibody titers were
transformed logarithmically to attain normality. Log10
antibody titers and SI values of different immunization
groups were statistically compared using the nested
design. The survival rates of different groups were ana-
lyzed by the chi-square test [10,20]. A P value of less than
0.05 was considered a statistically significant difference.
Results
Antigenicity of purified E. coli-based rSAG1
After cloning, the induced GST-SAG1 protein was puri-
fied and its tag GST protein was removed. The resulting
rSAG1 protein was analyzed by Western blot analysis
using the mouse mAb TG-1, which is specific to SAG1
of T. gondii tachyzoites. The result demonstrated that
rSAG1 protein (30 kDa) prepared in the present study
showed the native SAG1 antigenicity recognized by the
mouse mAb TG-1 (Figure 1).
Characteristics of PLG-rSAG1 microparticles
After PLG encapsulation, characteristics of PLG-rSAG1
microparticles were analyzed. The morphology of
PLG-rSAG1 microparticles was inspected by scanning
electron microscopy and showed a uniform population of
spherical particles with a smooth surface (Figure 2). A
particle size analyzer was further used to determine the
particle size from 4.25 to 6.58 μm in diameter (Table 1).
The entrapment efficiency for the rSAG1 protein ranged
from 69% to 81%, without significant differences (P>0.05,












Figure 1 Analysis of purified rSAG1 by Western blotting.
Purified rSAG1 was prepared as described in the Methods and
analyzed with anti-SAG1 mouse mAb TG-1 (lane 1). Standard protein
markers (lane M) are shown at the left.
Figure 2 Scanning electron micrograph of PLG-rSAG1
microparticles. The morphology of PLG-rSAG1 microparticles
was inspected by scanning electron microscopy and showed a
uniform population of spherical particles with a smooth surface
(bar represents 10 μm).
Table 1 Particle size and entrapment efficiency of PLG-
rSAG1 microparticles
Batch Mean particle size (μm)a Entrapment efficiency (%)b
TPV −1 5.71±2.32c 75±12d
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The in vitro release of rSAG1 from PLG microparticles in
PBS at 37°C was analyzed by the BCA protein assay
(Figure 3). The cumulative rSAG1 release in the super-
natant gradually increased over the course of a 35-day
period with three distinct phases. Within the first three
days, an initial burst released approximately 29.2% of the
total protein load. Afterwards, there was a very slow
release for 27 days followed by a rapid release during the
last 5 days. Altogether, 87.8% of the total protein load was
released from the microparticles during the 35-day study.TPV −2 4.25±1.26c 69±10d
TPV −3 6.58±2.69c 81±15d
a The particle size in diameter was measured and expressed as mean ± SD.
b The entrapment efficiency was expressed as a ratio of the actual rSAG1
entrapment to the theoretical rSAG1 entrapment as described in Methods.
c,dA significant difference (P<0.05) exists between batches with different
superscript letters.Antigenicity of released rSAG1
To further determine if released rSAG1 from PLG micro-
particles retained native SAG1 antigenicity, Western blot
analysis with use of mouse mAb TG-1, which is specific to
the surface antigen SAG1 of T. gondii tachyzoites, wasundertaken to examine released rSAG1 samples on days
1, 7, 14, 21, 28 and 35 (Figure 4). TG-1, which bound to
the soluble rSAG1 protein (Figure 4, lane 1), recognized
identical protein bands of 30 kDa displayed by the
released rSAG1 proteins collected on days 1, 7, 14, 21, 28
and 35 (Figure 4, lanes 2~7). Thus, the rSAG1 protein
retained the original SAG1 antigenicity following the
encapsulation process and during the release from micro-
particles. In other words, the released rSAG1 from PLG
microparticles prepared in our study had the potential to
induce anti-SAG1 immunity.SAG1-specific serum response of immunized mice
The ability of PLG-rSAG1 microparticles to trigger
humoral immunity against T. gondii in mice was subse-
quently evaluated. Western blot studies of sera obtained
two weeks after boosting showed that both PLG-rSAG1
microparticles and oil formulation rSAG1 (Vet L-10)
resulted in production of serum IgG antibodies against
the native SAG1 protein in TsoAg (Figure 5, lanes 1 and































Figure 3 In vitro release of rSAG1 from PLG microparticles over a 35-day period. A total of 5 mg of PLG-rSAG1 microparticles was
suspended in 1 ml of PBS (pH 7.4) with 0.02% sodium azide and shaken at 37°C in 1.5 ml microfuge tubes for 35 days. The amount of rSAG1 in
the supernatant sampled daily was measured using the BCA protein assay. The release studies were carried out in triplicate, with each point
representing the mean ± SD.
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nized with soluble rSAG1 alone, PLG or PBS did not
recognize anything in TsoAg (Figure 5, lanes 3~5).
Therefore, intraperitoneal immunization with rSAG1
could elicit a specific serum response to the native
SAG1 protein in TsoAg only when rSAG1 initially
formulated with adjuvants, but not in its soluble
form. These results were also consistent with those
from Figure 4 and emphasized again that the released
rSAG1 from PLG microparticles retained the native
SAG1 antigenicity to induce anti-SAG1 immunity. In
addition, the specific anti-Toxoplasma IgG titers of
mouse sera, collected every two weeks, were deter-
mined by ELISA (Figure 6). Four weeks after boosting
(the 6th week), IgG titers induced by PLG-rSAG1Figure 4 Antigenicity of rSAG1 released from PLG
microparticles. The soluble rSAG1 (lane 1) and released rSAG1
samples on days 1 (lane 2), 7 (lane 3), 14 (lane 4), 21 (lane 5), 28 (lane
6) and 35 (lane 7) were analyzed by Western blotting with mouse mAb
TG-1. Standard protein markers (lane M) are shown at the left.microparticles were significantly higher (P<0.05,
nested design) than those induced by rSAG1 (Vet L-10)
and, more importantly, the high titers were maintained till
the 10th week (Figure 6). Although high levels of anti-
bodies were also induced by rSAG1 (Vet L-10) in the first
six weeks, the levels gradually decreased starting from the
6th week to the 10th week (Figure 6). However, mice
immunized with soluble rSAG1 alone, PLG or PBS
displayed little, if any, anti-Toxoplasma IgG titersFigure 5 Antigenic specificity of mouse sera. Two weeks after
boosting, mouse sera were collected to analyze their antigenic
specificity. TsoAg was probed with sera from mice immunized with
PLG-rSAG1 microparticles (lane 1), rSAG1 (Vet L-10) (lane 2), soluble
rSAG1 alone (lane 3), PLG (lane 4) or PBS (lane 5). The mouse mAb
TG-1 (lane 6) was conducted as a positive control for the native SAG1




























Figure 6 IgG titers of mouse sera. Groups of mice were
intraperitoneally immunized twice (↑) with PLG-rSAG1 microparticles
(■ ), rSAG1 (Vet L-10)(● ), soluble rSAG1 alone (□ ), PLG (◊ ), or PBS (○ ).
Sera were collected from three mice per group every two weeks and
their anti-Toxoplasma IgG titers were determined by ELISA. Results
were presented as the mean of log10 titers ± SD.
*P<0.05 when






















Figure 7 Proliferation responses of mouse lymphocytes. Groups
of mice were intraperitoneally immunized twice (↑) with PLG-rSAG1
microparticles (■ ), rSAG1 (Vet L-10)(● ), soluble rSAG1 alone (□ ),
PLG (◊ ), or PBS (○ ). After priming, TsoAg-stimulated spleen
lymphocytes were prepared from three mice per group every two
weeks and their subsequent proliferation responses were analyzed
and expressed as stimulation index (SI) values. Results were
presented as the mean of SI values ± SD. *P<0.05 when comparing
the PLG-rSAG1 group to the rSAG1 (Vet L-10) group.
Table 2 IFN-γ production by spleen lymphocyte cultures
from immunized mice
Group IFN-γ (pg/ml) a
TsoAg Con A
PLG-rSAG1 1269 ± 193b 357 ± 45d
rSAG1 (Vet L-10) 545 ± 72c 362 ± 79d
rSAG1 < 20 353 ± 84d
PLG < 20 392 ± 65d
PBS < 20 348 ± 87d
a The production of IFN-γ in the culture supernatants of TsoAg- or Con A-
stimulated lymphocytes was calculated and expressed as mean ± SD.
b,c,dA significant difference (P<0.05) exists between groups with different
superscript letters.
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microparticles could elicit and prolong the high levels
of anti-SAG1 antibodies, indicating the importance of
use of the PLG adjuvant.
SAG1-specific lymphocyte proliferation of immunized
mice
After priming, TsoAg-stimulated spleen lymphocytes
were prepared from mice of different groups every two
weeks and their subsequent proliferation responses were
analyzed and expressed as SI values (Figure 7). Four weeks
after boosting (the 6th week), PLG-rSAG1 microparticles
elicited significantly higher SI values (P<0.05, nested design)
than rSAG1 (Vet L-10), and sustained high SI values till the
10th week (Figure 7). However, high SI values induced by
rSAG1 (Vet L-10) during the first six weeks gradually
decreased starting from the 6th week (Figure 7). Adminis-
tration with soluble rSAG1 alone, PLG or PBS induced
little lymphocyte proliferation in mice (Figure 7). Therefore,
encapsulation of rSAG1 in PLG microparticles also ren-
dered an enhanced and extended lymphocyte proliferation
response to the native SAG1 protein in TsoAg.
IFN-γ production of lymphocytes from immunized mice
To evaluate whether immunization with PLG-rSAG1
microparticles could induce a cell-mediated immune
response in mice, eight weeks after boosting (the 10th
week), the sandwich ELISA was used to analyze the abilityof spleen lymphocytes to produce IFN-γ, a cytokine
that plays an important role in cell-mediated immune
responses. Upon TsoAg stimulation, lymphocytes from
mice immunized with PLG-rSAG1 microparticles
produced significantly higher levels of IFN-γ (P<0.05,
ANOVA) than those from the rSAG1 (Vet L-10)
group (Table 2). However, rSAG1-, PLG-, or PBS-
administrated mice produced undetectable amounts of
IFN-γ (<20 pg/ml). As a control, lymphocytes from
all groups of mice were stimulated with T cell mito-
gen, Con A (0.5 μg/ml), and were found to produce
similar amounts of IFN-γ (P>0.05, ANOVA). There-
fore, the IFN-γ-associated cell-mediated immunity
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PLG-rSAG1 microparticles.
Protection against T. gondii tachyzoite challenge
We then determined whether PLG-rSAG1 microparti-
cles could confer effective protection in mice. Eight
weeks after boosting (the 10th week), all groups of 10
mice each were subcutaneously challenged with 1 × 104
live tachyzoites of T. gondii (RH strain). Animals were
observed daily for an additional month (28 days) and the
survival rates were recorded (Figure 8). All mice admini-
strated with soluble rSAG1 alone, PLG or PBS died
within 8 days after challenge and displayed no protection
against the challenge. Two out of 10 mice immunized
with rSAG1 (Vet L-10) survived during the challenge
study and showed a low protection of 20%. However,
only 2 mice died on the 21st day after challenge in the
PLG-rSAG1-immunized group with the highest survival
rate obtained in this group as 80%, which was signifi-
cantly higher (P<0.05, chi-square test) than that of the
rSAG1 (Vet L-10) group. Therefore, vaccination with
rSAG1 encapsulated with the PLG polymers provided a
substantial resistance to the experimental challenge of
T. gondii tachyzoites.
Discussion
Significant information obtained recently indicates that
future investigations on Toxoplasma vaccine develop-
ment will have to include adjuvants for enhancing the






























Figure 8 Survival of immunized mice after a lethal tachyzoite
challenge. Groups of mice were intraperitoneally immunized twice
with PLG-rSAG1 microparticles (■ ), rSAG1 (Vet L-10) (● ), soluble
rSAG1 alone (□ ), PLG (◊ ), or PBS (○ ). Eight weeks after boosting,
five groups of 10 mice each were subcutaneously infected with
1×104 live tachyzoites of T. gondii (RH strain). Animals were observed
daily for an additional month (28 days) and the final survival rates
were calculated. *P<0.05 when comparing the PLG-rSAG1 group to
the rSAG1 (Vet L-10) group.[6]. Different adjuvants capable of improving immune
responses and protection against T. gondii have been
described in numerous studies [7]. Among them, how-
ever, the biodegradable and biocompatible PLG polymers
are so far rarely used as an adjuvant in the development
of anti-Toxoplasma vaccines. To our knowledge, only
one study proposed by Stanley and coauthors [19] has
shown unexpected protection in sheep induced by a PLG
microparticle vaccine containing a tachyzoite extract plus
a mucosal adjuvant, cholera toxin. More effort is therefore
needed to improve not only the stability of encapsulated
Toxoplasma antigens but also the immune responses and
protection they induce in animals.
In the present study, we have successfully encapsulated
rSAG1 with PLG polymers and the resulting PLG-rSAG1
microparticles not only properly preserved the rSAG1’s
antigenicity (Figure 4) but also sustained the controlled,
stable release of the antigenic rSAG1 from PLG
microparticles (Figure 3). Peritoneal immunization
with the PLG-rSAG1 microparticles in mice further
enhanced and maintained SAG1-specific immunity for an
extended period (Figures 6 and 7) to protect mice from T.
gondii tachyzoite infection (Figure 8). However, an
immunity reduction starting from the 6th week to the
10th week in mice immunized with the oil formulation
rSAG1 (Vet L-10) revealed that the adjuvant effect of Vet
L-10 oil adjuvant is unable to maintain SAG1-specific
immunity. Therefore, the ability of PLG-rSAG1 micropar-
ticles to control the release rate of antigenic rSAG1 is a
particularly attractive characteristic.
In the present study, rSAG1 was encapsulated into PLG
microparticles by the double emulsion method [22], which
has been described to decrease contact between the antigen
and the organic solvent containing the PLG polymer [21].
After PLG encapsulation, Western blot analysis with
use of mouse mAb TG-1 further demonstrated that
the released rSAG1 from microparticles during the
35-day release period still showed the native SAG1
antigenicity (Figure 4), which led to production of
serum IgG antibodies against native SAG1 protein in
TsoAg (Figure 5). Furthermore, the lack of major
smaller or larger fragments of rSAG1 (as compared to
the soluble rSAG1) revealed that very little denaturation
or aggregation of the released rSAG1 occurred during the
35-day period (Figure 4). Even though we do not know if
the rSAG1 released from microparticles was 100% intact,
we reasonably believe that the antigenicity of released
rSAG1 remained high enough since it induced subsequent
immune responses (Figures 6 and 7) and protection
(Figure 8). These data indicate that both the encapsulation
procedure and release from microparticles in the present
study are not detrimental to the antigenicity of rSAG1.
As T. gondii is an obligate intracellular parasite, protective
immunity to T. gondii is largely mediated by Th1 cell-
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Th1-type cytokines, has been demonstrated to be a
decisive mediator of resistance to T. gondii [12]. Our
previous studies [10,20] and that recorded by others
[19] have shown that induction of both lymphocyte
proliferation and high IFN-γ production positively
correlates with protective Th1 cell-mediated immunity
against T. gondii. In the present study, therefore, we
concentrated much attention on the two activities of
spleen lymphocytes from immunized mice and the results
were used to judge whether protective Th1 cell-mediated
immunity is induced. We found that an increased proli-
feration to the native SAG1 protein in TsoAg was readily
observed in mice immunized with PLG-rSAG1 micropar-
ticles (Figure 7). More importantly, the enhanced proli-
feration response was extended till the 10th week
(Figure 7). Eight weeks after boosting (the 10th
week), maximum IFN-γ production was also detected
in mice immunized with PLG-rSAG1 microparticles
(Table 2). These findings indicate that immunization
with PLG-rSAG1 microparticles really elicits the
IFN-γ-associated Th1 cell-mediated immunity, which
is required for prevention of T. gondii infection.
In addition, our results are consistent with those of
previous studies, which have revealed that IFN-γ has
to be secreted for as long as possible in order to
maintain anti-Toxoplasma immunity [25,26]. The
maximum IFN-γ production eight weeks after boosting
(the 10th week) in mice immunized with PLG-rSAG1
microparticles (Table 2) could thus support the highest
SAG1-specific proliferation response (Figure 7). However,
the insufficient IFN-γ production in the rSAG1 (Vet L-10)
group (Table 2) did not maintain a high proliferation
response (Figure 7). These results further indicate that
PLG encapsulation is better than oil emulsification in
eliciting strong SAG1-specific IFN-γ production to main-
tain an anti-Toxoplasma immune response, indicating the
importance of use of the PLG adjuvant.
According to previous studies, a strong cell-mediated
immune response elicited by PLG microparticles appears
to be largely a consequence of their uptake into antigen
presenting cells (APCs) [15-18] and the delivery of these
microparticle-containing APCs to specific lymphoid
compartments [16,18] following vaccination. The par-
ticle size used for vaccination in animals is an important
parameter in enhancing APC uptake [15]. Particles smaller
than 10 μm in diameter are appropriate for direct uptake
by APCs [17], such as macrophages and dendritic cells,
that subsequently traffic to specific lymphoid compart-
ments [16,18], thereby initiating a specific immune
response [13-15]. The mean diameter of PLG-rSAG1
microparticles from different batches in the present study
is smaller than 10 μm (4.25~6.58 μm as indicated by
Table 1). The proper size range thus could stimulateperitoneal macrophages to facilitate the uptake of PLG-
rSAG1 microparticles administered in the mouse periton-
eal cavity. The microparticle-containing macrophages
then traveled to other lymphoid compartments, in-
cluding the spleen, and effectively presented SAG1
epitopes to T lymphocytes, especially Th1 and Tc,
thereby inducing strong SAG1-specific Th1 cell-
mediated immunity as shown in Figure 7 and Table 2.
Therefore, facilitation of uptake and delivery of PLG-
rSAG1 microparticles by macrophages can lead to more
effective antigen processing and presentation to T lympho-
cytes capable of inducting cell-mediated immune responses
[27,28]. However, the oil formulation rSAG1 (Vet L-10)
used in this study could not result in more effective rSAG1
uptake and delivery than those induced by PLG-rSAG1
microparticles, and thus caused a weak Th1 cell-
mediated immunity (low proliferation and IFN-γ
production).
More importantly, the immune responses induced by
PLG-rSAG1 microparticles protected mice (80%) against
a lethal subcutaneous challenge of 1 × 104 T. gondii
tachyzoites (RH strain) (Figure 8), an amount 10 times
higher than that we had previously determined to be
optimal for use as a challenge dose at 10 LD50 [20], and
enabled mice to survive for a long period of 28 days after
challenge. Thus, the high survival rate and long survival
period in mice encouraged us to believe that PLG-rSAG1
microparticles strongly induce a protective immune
response (Th1 cell-mediated immunity) to eliminate
tachyzoite-infected cells and to subsequently limit
parasite dissemination during the experimental tachyzoite
challenge [11].
In addition to cell-mediated immunity, an enhanced
and extended anti-SAG1 IgG response detected in
mouse serum following immunization with PLG-rSAG1
microparticles (Figures 5 and 6) also indicates that
systemic humoral immunity mediated by B cells may
participate in the resistance to T. gondii infection.
Although the role of IgG antibodies in anti-Toxoplasma
immunity is unclear, a general assumption has been pro-
posed that serum IgG antibodies play a partial role in
the prevention of secondary T. gondii infection [29,30].
Based on the results in the present study, peritoneal
immunization with the SAG1 microparticle vaccine in
BALB/c mice can induce not only significant long-lasting
SAG1-specific humoral and cell-mediated immune
responses but also high protection against T. gondii tachy-
zoite infection. DNA vaccination for the induction of both
specific humoral and cellular immune responses against a
lethal tachyzoite challenge has been studied in mice
[31,32]. However, in comparison, PLG-rSAG1 microparti-
cles prepared in the present study provide a much higher
protection rate (80%) in BALB/c mice than the GRA6
DNA vaccine (53.3%) [32]. In addition, only survival
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observed in BALB/c mice immunized with another DNA
vaccine, pSAG1/14-3-3 [31]. We therefore propose that
PLG-rSAG1 microparticles may be superior to Toxoplasma
DNA vaccines in protecting mice from the acute tachyzoite
infection. However, due to critical influences of the parasite
genotypes (types 1, 2 and 3) [33] and host susceptibility
[34] on disease progression and severity of toxoplasmosis,
the protective efficacy of Toxoplasma vaccines should be
evaluated with different T. gondii strains and different host
models. Further studies are therefore needed to confirm
whether administration with PLG-rSAG1 microparticles
protects different animal models from an oral challenge of
T. gondii cysts (types 2 and 3), which imitates the natural
infection initiated by ingesting oocysts released in cat faeces
or consuming meat from infected animals containing the
long-lived tissue cysts [1,6].
Conclusions
We have successfully encapsulated rSAG1 with PLG
polymers to produce PLG-rSAG1 microparticles that
can sustain the stable release of antigenic rSAG1 for a
long time (35 days). In addition, PLG-rSAG1 microparti-
cles administered in the mouse peritoneal cavity enhance
and maintain protective SAG1-specific humoral and
cell-mediated immune responses for an extended period
(10 weeks) to protect mice from T. gondii tachyzoite
infection. The capability of this microparticle vaccine to
control the stable release of antigenic rSAG1 and effec-
tively induce and extend protective immunity would be
advantageous for its application in the development of
long-lasting vaccines against T. gondii for future use in
humans and animals.
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